Forty Seven Inc. said the U.S. Food and Drug Administration granted fast-track designation to its investigational blood cancer therapy magrolimab.
![]() |
The Menlo Park, Calif.-based company is developing magrolimab as a potential treatment for myelodysplastic syndrome and acute myeloid leukemia. The former is a group of disorders that occur when the blood-forming cells in the bone marrow do not work properly; the latter is a cancer of the blood and bone marrow in which the bone marrow produces too many abnormal white blood cells known as myeloblasts.
The experimental drug, a monoclonal antibody against CD47, works by blocking the "don't eat me" signal used by cancer cells to avoid being absorbed by a type of white blood cells called macrophages.

